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Abbreviations 
 
ACS acute coronary syndrome 
ADP adenosine diphosphate  
AMP adenosine monophosphate 
APC activated protein C  
APTT activated partial thromboplastin time 
APY apyrase 
ARC AR-C69931MX 
ASA acetylic salicylic acid, aspirin 
AT antithrombin 
ATP adenosine triphosphate 
AU aggregation unit 
AUC area under the aggregation curve  
C4BP complement 4 binding protein 
CaCl2 calcium-chloride 
cAMP cyclic adenosine monophosphate 
CFT clot formation time 
CI confidence interval  
COX1 cyclooxygenase-1  
CT clotting time 
DRVV diluted Russell's viper venom 
DVT deep vein thrombosis  
EC50 half maximal effective concentrations   
ETP endogenous thrombin potential  
FII coagulation factor II, prothrombin 
FV coagulation factor V 
FVIII coagulation factor VIII 
FVQ506 factor V Leiden 
FX coagulation factor X 
FXa activated factor X 
FXIIa activated factor XII 
G gauge 
G/l giga per litre 
GP glycoprotein 
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IC50  half maximal inhibitory concentrations  
IP3 inositol triphosphate 
LA lupus anticoagulant 
LMWH low molecular weight heparin 
LTA light transmission aggregometry  
MA maximal amplitude 
MCF maximum clot firmness 
MEA multiple electrode aggregometry  
min minute 
MRS MRS2179 
n number 
OR odds ratio  
p probability, statistical significance 
PA platelet aggregation 
PAR-1 proteinase activated receptor 1 
PC protein C 
PGE1 prostaglandin E1  
PKC protein kinase C 
PLC phospholipase-C  
PRP platelet-rich plasma 
PS protein S 
PT prothrombin time 
ROTEG rotation thrombelastography 
SD standard deviation 
SPC single platelet counting 
TEG thrombelastography 
ThP thrombophilia 
TRAP-6 thrombin receptor-activating peptide-6  
TT thrombin time 
TxA2 thromboxan A2 
U/ml unit per millilitre 
VASP vasodilator-stimulated phosphoprotein 
VTE venous thromboembolism 
vWF von Willebrand factor 
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1. Introduction 
 
Haemostasis is a very complex and well regulated process, which is 
designed to maintain blood in a fluid state under physiologic conditions, but it is 
primed to react to vascular injury in an explosive manner to stem blood loss by 
sealing the defect in the vessel wall. The three “traditional” components of 
haemostasis are the endothelium, the platelets and the coagulation system. The 
participation of platelets in haemostasis is a fundamental component of this 
physiologic process. The reactions involved include adhesion to the cut end of a 
blood vessel, spreading of adherent platelets on the exposed subendothelial surface, 
secretion of stored platelet constituents, and formation of large platelet aggregates. 
In addition, platelet membrane sites become available for adsorption and 
concentration of clotting factors, and plasma coagulation is accelerated, resulting in 
the formation of a fibrin network that reinforces the otherwise friable platelet plug. 
The firm platelet-fibrin clot subsequently retracts into a smaller volume, a process 
that is also platelet-dependent [1]. These two main components of haemostasis – 
platelets and plasmatic proteins - are interdependent. The importance of leukocytes 
in coagulation and fibrinolysis has also been established [2,3]. The platelet adhesion 
process is different under different shear conditions, for example at high shear rates 
plasma von Willebrand factor (vWF) and glycoprotein (GP) Ib/IX are required, 
while at low shear rates other proteins are sufficient for the adhesion of platelets. 
Several laboratory assays have been designed to measure haemostasis. First, 
simple haemostatic tests, like bleeding time and coagulation time were used, which 
were mainly made for the detection of hemorrhagic diatheses. Then plasma-based 
global haemostatic assays were developed, like activated partial thromboplastin 
time (APTT) and prothrombin time (PT), which could be automated and are now 
widely used in routine laboratories. However, these tests are robust, unable to detect 
mild defects and to show the location of the disorder. With the development of 
single factor determinations this problem was thought to be have been solved, but 
clinical experience showed that certain haemostasis abnormalities could not be 
diagnosed by them. Additionally, single factor determinations without good 
screening assays are very costly. As we get more and more information about 
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physiological haemostasis, there is a tendency to develop methods, which can better 
model the physiological conditions, such as flow conditions and shear, and the use 
of whole blood is preferred. The methods using whole blood testing are good 
candidates for point of care testing, so the test can be used even in acute situations.  
 
1.1. Epidemiology and importance of haemostatic abnormalities 
 
Haemostasis is the consequence of balanced interactions of cellular and 
molecular components responsible for the maintenance of an intact circulation [4]. 
Dysfunction of cells or proteins participating in the haemostasis system may result 
in thrombophilia or a haemorrhagic diathesis.  
 
1.1.1. Bleeding disorders 
 
Haemostatic imbalance may be inherited or acquired. A wild range of 
inherited bleeding disorders have been described, originating from an inadequate 
function of the platelets as seen in Glanzmann’s disease and the Bernard Soulier 
syndrome, or caused by deficiency in procoagulant proteins such as fibrinogen or 
coagulation factor II, V, VII, VIII, IX, X, XI and XIII. Some bleeding disorders 
such as inherited FV and FX deficiency are rare, occurring only in one per million 
inhabitants. Other bleeding disorders, such as haemophilia A are more common, 
occurring in 1:10000 [1].  
 
1.1.2. Thromboembolic disease 
 
Hypercoagulable states can present themselves as arterial or venous 
thromboembolic disease.  
The major cause of death and disability in the developed world is arterial 
vascular disease. Its main etiological factor is atherosclerosis, along with 
embolisation mainly of cardiac origin. Depending on the affected part of the arterial 
branch, we can talk about cardiovascular, cerebrovascular, aortic, peripheral and 
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renal vascular disease. Symptoms develop when growth or rupture of the plaque 
reduces or obstructs blood flow; symptoms vary with the affected arteries. 
In recent years, age-related mortality attributable to atherosclerosis has been 
decreasing, but in 2005, cardiovascular diseases, primarily coronary and 
cerebrovascular atherosclerosis still caused almost 870,000 deaths in the US (more 
than cancer and almost 9 times more than injuries) [5]. Atherosclerosis is rapidly 
becoming more prevalent in developing countries, and as people in developed 
countries live longer, incidence will further increase. By 2020, atherosclerosis 
among cardiovascular diseases is expected to be the leading cause of death 
worldwide. Eastern European countries such as the Ukraine, the Russian Federation, 
Hungary, and the Czech Republic have among the highest and increasing CVD rates 
in the world, which is in marked contrast to most economically stable European 
countries where declines in CVD mortality rates have been experienced over the 
past 30 years [6]. 
 
Deep vein thrombosis (DVT) and pulmonary embolism represent different 
manifestations of the same clinical entity, which is referred to as venous 
thromboembolism (VTE). The incidence rate of a first venous thrombosis is 1 to 2 
events per 1000 patient-years [7]. According to population studies, the average 
annual incidence rates of VTE was 117 per 100 000 person-years [8]. Venous 
thromboembolism is predominantly a disease of older age. Incidence rates increase 
markedly with age for both men and women and for both deep vein thrombosis and 
pulmonary embolism [8,9]. The overall age-adjusted incidence rate is higher for 
men than women (male:female sex ratio is 1.2:1) [8]. Pulmonary embolism 
accounts for an increasing proportion of VTE with increasing age for both genders 
[8]. Venous thromboembolism recurs frequently; about 30% of patients develop 
recurrence within the next 10 years [10]. The hazard of recurrence varies with the 
time since the incident event and is highest within the first 6–12 months.  
At least 1 out of 5 of the venous thromboembolism cases is fatal, although 
available autopsy data suggest that this figure is probably a significant 
underestimation of actual mortality. In Hungary, the mortality rates of venous 
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thromboembolism were 10.8, 19.8 and 10.7 per 100000 inhabitants in the years 
1970, 1990 and 1999, respectively [11,12]. Moreover, pulmonary embolism 
accounts for 5-10% of deaths in hospitalized patients, making VTE the most 
common preventable cause of in-hospital death [13].  
Morbidity is also associated with two long-term complications: chronic 
thromboembolic pulmonary hypertension and post-thrombotic syndrome. Chronic 
pulmonary thromboembolism with pulmonary hypertension is seen in up to 5% of 
patients as a result of the incomplete resolution of a thrombus [14]. These patients 
are functionally limited because of progressive exertional dyspnoea, chest pain, 
syncope, and lower extremity oedema. Post-thrombotic syndrome is characterized 
by leg pain, oedema, other signs of venous insufficiency, and eventually leg 
ulceration as a result of prolonged venous hypertension. At least 30% of patients 
with venous thromboembolism develop this chronic debilitating disease [15].  
In some cases, risk factors for both venous and arterial disease may be 
present, making the clinical picture more complex [16]. 
 
1.2. The role of haemostatic investigations in arterial thrombotic disease  
 
Thrombosis plays a central role in the pathogenesis of acute coronary 
syndrome (ACS); this is supported by the presence of thrombi at the site of a 
ruptured coronary plaque at autopsy, in atherectomy specimens from patients with 
unstable angina, and on angioscopy and angiography of patients with unstable 
angina. Indirect evidence of ongoing thrombosis in ACS is provided by the 
elevation in levels of markers of platelet activation and fibrin formation. 
Additionally, a marked improvement in the clinical outcome of patients with ACS 
is achieved with specific antithrombotic therapy using acetylsalicylic acid (aspirin), 
heparin, platelet GP IIb/IIIa inhibitors and clopidogrel. Because of the central role 
of platelets in the pathophysiology of ACS, antiplatelet therapy is one of the 
cornerstones of therapy and is directed at decreasing the formation of TxA2 
(aspirin), inhibiting the adenosine diphosphate (ADP) receptor pathway of platelet 
activation (ticlopidine and clopidogrel), and directly inhibiting platelet aggregation 
(GP IIb/IIIa inhibitors) [1]. The efficacy of various antiplatelet agents in preventing 
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cardiovascular and thrombotic complications has been established in large-scale 
clinical trials. Composite data from such studies tend to mask individual 
responsiveness to the drugs being investigated. In fact, antiplatelet drugs that are 
effective and safe in one individual may be ineffective or harmful in another [17].  
According to laboratory measures of platelet activation and aggregation a 
large proportion of people fail to respond in the anticipated manner when treated 
with aspirin, they are thus termed “aspirin resistant” [18,19]. The clinical relevance 
of aspirin resistance was recently demonstrated in a study of stable patients with 
cardiovascular disease who were found to have a greater than threefold increase in 
the risk of major adverse events during long-term follow-up compared with those on 
aspirin who exhibited normal inhibition of platelet aggregation [20].  
The thienopyridines ticlopidine and clopidogrel inhibit platelet function by 
irreversibly blocking the binding of ADP to its P2Y12 platelet receptor. Both of 
these drugs are inactive and require conversion to their active platelet-inhibitor 
metabolites by the hepatic cytochrome P450 system in vivo. Clopidogrel has a more 
favourable side effect profile and a more rapid onset of action than does ticlopidine 
[21,22]. Interindividual variability in platelet inhibition by clopidogrel and the 
occurrence of "clopidogrel resistance" has been recently documented by several 
groups [23-26]. Although not conclusively demonstrated, one study suggested that 
clopidogrel resistance increases the risk of coronary stent thrombosis [26]. It is also 
becoming increasingly clear that there is considerable intrinsic variability in the 
responsiveness of individuals to antiplatelet agents, which is mostly genetically 
determined. There is growing evidence that differences in the effect of not only 
aspirin, but also clopidogrel is of clinical importance [26-31].  
This widespread use of antiplatelet therapy in cardiovascular medicine and 
evidence suggesting a clinically relevant drug resistance have created a demand for 
simple assays to determine the effectivity of antiplatelet treatment. Point-of-care 
platelet function testing in acute settings and rational pharmacogenomic approaches 
would permit more individualized treatment, in some cases requiring dosing 
changes or the use of alternate drugs to optimize antiplatelet therapy. The clinical 
value of the so far known point-of-care technologies, such as the platelet function 
analyzers PFA-100 (Dade-Behring) and VerifyNow (Accumetrics), remains to be 
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proved convincingly [32]. Optical platelet aggregometry is still accepted as gold 
standard, but this is not a standardized method [33]. Preanalytical interferences 
related to blood sampling and complicated sample processing add substantial 
technical imprecision to the already large biological variability of platelet 
aggregation. Optical aggregometry requires expert personnel and time-consuming 
centrifugation steps to obtain platelet-rich and platelet-poor plasma. Aggregation 
correlates with the increase of light transmittance in platelet-rich plasma (PRP) after 
addition of a platelet agonist. However, PRP is an artificial milieu deficient in giant 
platelet subspecies as well as erythrocytes and leukocytes, which are regarded as 
critical modulators of platelet function in vivo [34]. Thus, whole blood platelet 
aggregometry has several advantages. We were the first to describe a new, 
promising whole blood aggregometry, called multiple electrode aggregometry 
(MEA) and thus prepare it for further studies.  
 
1.3. The role of haemostatic investigations in venous thromboembolism 
 
Venous thromboembolism is now recognized as a complex, multifactorial 
disease, involving both environmental exposures (e.g. clinical risk factors) and both 
genetic and environmental interactions [35]. Environmental risk factors include 
immobilization, surgery, malignancies, pregnancy, puerperium, and exogenous 
female hormones [36]. Genetic abnormalities increasing the risk of a thrombotic 
event have been known for several decades and include deficiencies of the natural 
anticoagulants antithrombin (AT), protein C (PC), and protein S (PS). Additional 
biochemical risk factors for a thrombotic event are factor V Leiden (FVQ506), 
prothrombin (FII) G20210A, high levels of factors VIII, IX, or XI, homocysteine, 
and fibrinogen [37-43]. A certain combination of risk factors is necessary, each 
adding to the thrombotic event potential, to exceed the thrombosis threshold and put 
an individual at risk.  
In order to improve survival, avoid recurrence, prevent complications, and 
reduce health care costs, the occurrence of VTE must be reduced. To reduce VTE 
incidence, persons at risk for VTE must first be identified. Thrombophilia (the 
tendency to develop thrombosis) can be inherited, acquired, or both. Recent family 
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based studies indicate that VTE is highly inheritable and follows a complex mode 
of inheritance involving environmental interaction [44-46]. Still, many cases of 
venous thromboembolism remain „idiopathic”.  
Studies hold the potential for further stratifying individual patients into high- 
and low-risk for incident and recurrent VTE, targeting prophylaxis to those who 
would benefit most, and ultimately, reducing the occurrence of VTE [35]. However, 
extensive testing for the presence of a thrombophilic state is quite costly. Screening 
should be reserved for patients who sustain their first event prior to 50 years of age, 
have a history of recurrent events, or who have a first-degree relative with a venous 
thromboembolic event that also occurred prior to the age of 50 [47].  
According to the “Guidelines of the Ministry of Health: The prevention and 
treatment of thromboembolism”, thrombophilic state can be divided into two types: 
A. Mild thrombophilia: negative family history, the first VTE occurs after 
45 years of age. In this case the recommended examinations are: activated protein C 
(APC)-resistance, FVQ506 and FIIG20210A mutation, lupus anticoagulant (LA), 
fasting homocysteine level. The occurrence of multiple genetic defects is 1-2%. 
B. Severe thrombophilia: the first VTE event occurs prior to 45 years of age, 
recurrent VTE, have a first-degree relative with a venous thromboembolic event 
that also occurred prior to the age of 45. In this case the recommended examinations 
are: AT, PC, PS activity, APC-resistance, FVQ506 and FIIG20210A mutation, LA, 
fasting homocysteine level. The occurrence of multiple genetic defects is ca. 10%. 
In a group of patients with a history of VTE only 40-70% has an underlying 
thrombophilia (depending on the inclusion criteria). This can be explained from the 
existence of not yet identified prothrombotic abnormalities, which hold the same 
thrombotic event potential as the known prothrombotic abnormalities or the 
presence of acquired risk factors.  
Additionally, the diagnosis of the various haemostatic disorders using 
routine laboratory tests and single factor determinations is time consuming and/or 
expensive. There is no single haemostasis laboratory test that has the capacity to 
accurately illustrate the clinical effects of procoagulant or anticoagulant 
interventions up to now, and is capable of diagnosing overall hypocoagulation or 
hypercoagulation states of blood. Thrombelastography, which is a global 
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haemostatic method, is potentially capable of diagnosing thrombophilic states in the 
most natural environment: whole blood. We will discuss the applicability of rotation 
thrombelastography in detection of thrombophilia in VTE patients. 
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2. Multiple electrode aggregometry 
 
2.1. Introduction 
 
The study of the role of platelets in the pathogenesis of ischemic vascular 
diseases and the monitoring of anti-platelet drug effects in patients with cardio- and 
cerebrovascular diseases require reliable platelet function tests. Several techniques 
are in use to measure platelet aggregation.  
The most commonly used method is light transmission aggregometry (LTA, 
“Born” aggregometry) employing citrated or heparinised PRP [48]. Disadvantages 
of this technique include the need of centrifugation to separate other blood cells 
from platelets, which are also known to influence platelet function [49,50]. Besides, 
PRP does not contain every blood platelet. The platelet recovery rate is only 61 to 
90% of total, depending on the separation methods used [51,52]. This usually leads 
to the loss of giant platelets which may be both hypo- and hyperactive [53]. All 
these factors may artificially alter the measured platelet aggregation response. For 
these reasons, novel methods have been introduced to measure platelet aggregation 
in whole blood.  
Single platelet counting (SPC) is one of these methods, which is 
characterized by the measurement of the loss of platelets after stimulation of 
anticoagulated blood by using conventional haematology analyzers, which has been 
described in detail in [54], and is widely used [55-59]. Single platelet counting, 
however, does not differentiate between micro- and macroaggregates. 
Measurements of aggregation kinetics are laborious, since it requires the 
measurement of platelet count for each time point.  
Another method to measure platelet aggregation in whole blood is 
impedance aggregometry, which was introduced by Cardinal and Flower [60]. It is 
based on the attachment of platelets on two platinum electrodes, which results in an 
increase of electrical resistance between the electrodes. The change of resistance 
(called “impedance” as an alternating current is applied in order to prevent 
electrolysis) is continuously recorded. This is proportional to the amount of platelets 
sticking to the electrodes. Riess et al. compared whole blood impedance 
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aggregometry with LTA of PRP [61]. They found that there was a good correlation 
between the two techniques when aggregation was induced by ADP or collagen. As 
compared with PRP, impedance aggregometry in whole blood was more sensitive to 
the aggregating effect of thrombin, ristocetin, and arachidonic acid, or to the 
inhibitory effect of prostacyclin or aspirin [61]. Platelet function in lipemic blood 
can also be evaluated by impedance aggregometry [62]. However, impedance 
aggregometry, as realized in commercial instruments (e.g. Chrono-log®) has some 
problems. The re-usable electrodes have to be cleaned between analyses, which is 
impractical and a possible source of error.  
For these reasons, a novel instrument to measure platelet aggregation in 
diluted whole blood by impedance aggregometry has been developed. This 
instrument uses disposable test cells with duplicate impedance sensors. The method 
is called multiple electrode aggregometry (MEA) because it uses 4 electrodes per 
test cell.  
 
2.2. Aims of the study with multiple electrode aggregometry 
 
1. Validating this novel impedance aggregometry method by using platelet 
agonists ADP and collagen, considered as the most important agonists in 
atherosclerotic conditions and furthermore thrombin receptor-activating peptide 
(TRAP)-6, which powerfully mimics the effects of thrombin exerted on proteinase 
activated receptor 1 (PAR-1). 
  
2. Examining the in vitro effect of two anticoagulants: the commonly used 
sodium citrate (12.9 mmol/l) and the direct thrombin inhibitor hirudin.  
 
3. Comparing MEA to another sensitive method for platelet aggregation: 
single platelet counting, using the same agonists.  
 
4. Evaluating the in vitro platelet aggregation inhibitory effects of aspirin 
and the ADP scavenger enzyme apyrase as measured by MEA and SPC. 
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5. Investigating the contribution of the two platelet ADP receptors (P2Y1 
and P2Y12) in platelet aggregation by using the P2Y1 and P2Y12 antagonists, i.e. 
MRS2179 and AR-C69931MX. 
 
6. Testing MEA’s ability to detect the aggregation inhibitory effect of per os 
clopidogrel treatment ex vivo, exhausting the synergistic effect of prostaglandin E1 
(PGE1). 
 
 
2.3. Materials and methods 
 
2.3.1. Materials 
 
ADP, epinephrine, apyrase (grade VII), the ADP receptor P2Y1 antagonist 
MRS2179 and PGE1 came from Sigma (Taufkirchen, Germany), acetylsalicylic 
acid from Fluka. Collagen (Horm) was obtained from Nycomed Pharma (Munich, 
Germany), tri-natriumcitrate dihydrate was from Merck (Darmstadt, Germany). The 
ADP receptor P2Y12 antagonist AR-C69931MX (2-trifluoropropyltio-N-(2-
(methylthio)ethyl)-β,8dichloromethylene ATP) was a gift from AstraZeneca R & D 
Charnwood (Loughborough, United Kingdom). As hirudin, recombinant lepirudin 
(Refludan, Schering AG, Germany) was used. TRAP-6 (SFLLRN-OH, thrombin 
receptor activating peptide-6) was obtained from Dynabyte Medical (Munich, 
Germany). Clopidogrel was Iscover from Bristol-Myers Squibb Pharma EEIG 
(Uxbridge, UK).  
 
2.3.2. Preparation of blood 
 
Blood was collected from healthy volunteers using a 19 G needle and plastic 
syringe containing either 1/10 volume recombinant hirudin (final concentration in 
blood ~200 U/ml; 13 µg/ml) or 1/10 volume sodium citrate (final concentration in 
blood 12.9 mmol/l) or using 5 ml Vacutainer tubes with buffered citrate with the 
same final concentration of sodium citrate after informed consent was obtained. All 
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volunteers denied taking any medication which might affect platelet function in the 
two weeks preceding the experiments.  
For some experiments, acetylic salicylic acid (ASA, final concentration in 
blood 1 mmol/l) was dissolved in the sodium citrate solution or saline solution 
before addition of hirudin, to achieve total dissolvement. In case of the ex vivo 
experiments, blood was taken from six healthy volunteers before and 3, 6 and 78 
hours after administration of the first dose of clopidogrel (300 mg loading dose on 
day 1 and 75 mg on day 2, 3 and 4) and at least 2 weeks after the last drug 
ingestion. Measurements were performed between 0.5 and maximal 4 hours after 
venipuncture. The blood was kept in closed polyethylene tubes at room temperature 
during the experiment.  
 
2.3.3. Measuring platelet aggregation by multiple electrode aggregometry  
 
 Whole blood aggregation was determined using a new generation 
impedance aggregometer (Multiplate® analyser, Dynabyte Medical, Munich). The 
device has 5 channels for parallel tests, and a single use test cell with duplicate 
impedance sensors, each consisting of 2 straight electrode wires (blood contacting 
area: 3 mm length, 0.3 mm diameter for each sensor wire). The impedance change 
determined by each sensor is recorded independently. Due to the use of 2 duplicate 
electrodes per test cell the technique is called “multiple electrode aggregometry” 
(MEA). The instrument is called “Multiplate”, short for “multiple platelet function 
analyzer”, indicating the multiplicity of channels and sensors per channel of the 
device. During the analysis the sample-reagent mixture is stirred using a discardable 
PTFE (poly-tetra-fluoro-ethylene) -coated magnetic stirrer (800 U/min) (Figure 
2.1.).  
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Figure 2.1. Picture of the Multiplate® analyzer (left) and a discardable test cell 
(right).  
 
 
In order to prepare a 1:1 dilution of whole blood, first preheated (37° C) 
saline (288 µl) was placed into the test cells.  Into the saline we added 12 µl of the 
appropriate dilutions of inhibitors or other test substances; the ADP scavenger 
apyrase (final concentration 10 U/ml), the P1Y1 receptor inhibitor MRS2179 (final 
concentrations from 0.1 µmol/l to 200 µmol/l), the P1Y12 receptor inhibitor AR-
C69931MX (final concentrations from 0.1 nmol/l to 2000 nmol/l), the prostaglandin 
PGE1 (final concentrations 6 or 10 nmol/l, depending on the anticoagulation used), 
CaCl2 for recalcification of citrated blood (final concentration 2 mmol/l) or 12 µl 
saline for control tests to reach 300 µl volume. Afterwards we added 300 µl of 
anticoagulated whole blood - with or without aspirin, as described above (Figure 
2.2.).  
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Figure 2.2. Algorythm of the Multiplate measurements.  
288 ul saline 
12 µ l of either of: 
• apyrase 
• MRS2179 
• AR-C69931MX  
• PGE1  
• CaCl2 
• saline  
300 µ l of whole blood 
anticoagulated by 
citrate or hirudin         
(± aspirin) 
12 µ l of either of 
the agonists:  
• ADP 
• collagen  
• TRAP-6 
• saline 
 
In one experimental series, a special version Multiplate apparatus with a 
different stirring device was tested in order to analyze the effect of turbulence on 
platelet aggregation. In this apparatus, the stirrer was turned alternately to the right 
and left by 180°. In order to attain sufficient flow in the cup a larger (6x3 mm vs. 
4x2 mm) stirrer was applied.  
After 3 minutes of incubation and stirring at 37°C, the measurements were 
started by adding 12 µl of the appropriate agonist solution or saline to the 1:1 
diluted blood. The impedance change caused by the adhesion and aggregation of 
platelets on the electrode wires was continuously detected. The results registered by 
the two sensors provided two aggregation curves. The two curves typically did not 
differ much; if they did, the measurement was considered to be faulty and was 
repeated. This difference was only roughly estimated but only occurred in less than 
5% of the tests. In this way the duplicate sensors serve as an internal control. The 
mean values of the two determinations are expressed in arbitrary “aggregation 
units” (AU). The test time was typically 5 minutes. The area under the aggregation 
curve (AUC) was used to express the aggregation response over the measured time 
(AU*min) (Figure 2.3.). 
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Figure 2.3. Schematic picture of platelet aggregation on the surface of the electrodes 
(above, left) and an electronmicroscopic picture of a platelet aggregate (above, 
right, from [63]). A typical test curve (down) with two parallel aggregation curves 
and the measured parameters. (*1 Ohm equals approximately 8 AU.) 
 
Aggregation was triggered using ADP, collagen or TRAP-6. Platelet 
aggregation did not alter from 30 to 240 minutes after venipuncture (data not 
shown) when measured by MEA. The method’s reproducibility (intra-assay 
variability) was found to be 6±3% (mean coefficient of variations [%CV] ±SD, 
n=8). 
The maximal aggregation (AU) and the area under the aggregation curve 
(AUC) showed a linear correlation in case of ADP and TRAP-6 -induced platelet 
aggregation. The correlation was exponential in the case of collagen-induced 
platelet aggregation.  
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2.3.4. Single platelet counting 
 
Single platelet counting (SPC) was performed as previously described by 
Fox et al., and Haseruck et al. [54,59], with the exception that diluted blood (1:1 
dilution with saline) was used in order to make the results comparable with those of 
the MEA measurements. Aliquots of diluted blood (15 µl) were removed from the 
Multiplate® test cells just before adding the agonist or saline, or at different times 
after addition of the agonist, and transferred into a fixation buffer (30 µl). The 
fixation buffer consisted of NaCl (150 mmol/l), Na2EDTA (4.6 mmol/l), Na2HPO4 
(4.5 mmol/l), KH2PO4 (1.6 mmol/l) and formaldehyde (0.16 w/v%) (pH 7.4).  Fixed 
samples were counted using the Sysmex Platelet Counter PL-100 (TOA Medical 
Electronics, Kobe, Japan). In the counter, the blood particles (diluted according to 
the instructions) pass through the small aperture of the transducer where an electric 
signal is produced. The size of this signal is directly proportional to the size of the 
particle. After counting and a subtraction process, the number of the particles of the 
size of a single platelet is arrived at. Percentage aggregation was calculated as 
percentage loss of single platelets compared to baseline count. All platelet counts 
were done in duplicate.  
 
2.3.5. Manual platelet counting 
 
To measure platelet concentration in blood from individual donors, 
anticoagulated blood (20 µl) was diluted with 2 ml Thrombo Plus (Sarstedt, 
Germany) haemolysis buffer and platelets were counted in a Neubauer chamber 
according to the manufacturer’s instructions.  
Platelet concentrations of blood from different donors ranged between 164 
and 395 G/l. Platelet aggregation induced by ADP (5 µmol/l) (Figure 2.4.) or 
collagen (2.5 µg/ml) (not shown) seemed to be independent of the platelet 
concentration in the normal range, regardless of whether blood was anticoagulated 
with citrate or hirudin.  
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Figure 2.4. Independence of platelet aggregation from thrombocyte concentration. 
Maximal platelet aggregation induced by 5 µmol/l ADP was measured by multiple 
electrode aggregometry in citrated (A, n=22) or in hirudin-anticoagulated (B, n=16) 
blood. Statistical analysis was performed by linear regression analysis. 
 
 
2.3.6. Phase contrast microscopy 
 
In some cases, after an aggregation reaction was completed, the Multiplate® 
electrodes with the adherent thrombocytes were carefully washed 3-4 times with 
PBS buffer and then fixed with 3.7 % formaldehyde for 10 minutes at room 
temperature. After a PBS wash, the electrodes were carefully cut off, placed on a 
glass slide and covered with Moviol and a glass cover slip. Phase contrast 
microscopy was performed using an inverse Zeiss microscope (Axiovert 200 M) 
and the corresponding Axiovision software. 
 
2.3.7. Statistical analysis 
 
Results are reported as mean ± SD from 4-8 experiments conducted on 
different blood samples. Intra-assay, intra- and interindividual variabilities were 
expressed as %CV (coefficient of variations, calculated as SD/mean x 100). Intra-
assay variability was determined in two independent donors by assaying the same 
blood 4 times simultaneously. Half maximal effective concentrations (EC50) were 
generated manually from every single dose-response curve, based on the following 
equation: Y50=(ymax-ymin)/2+ymin, the fitting X50 was read from the graph (where 
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Y50: half of maximal aggregation, ymax: maximal  aggregation (AUC), ymin: control, 
without platelet stimulus AUC). Subsequently, the EC50s were statistically 
evaluated (mean ± SD, t-tests). Half maximal inhibitory concentrations (IC50) were 
determined correspondingly. Statistical comparisons of samples were performed by 
paired and unpaired Student`s t-test or linear regression analysis using Microsoft 
Excel 2000. Differences were considered significant when p was < 0.05. 
 
2.4. Results 
 
2.4.1. Spontaneous platelet aggregation and ADP-, collagen- and TRAP-6-induced 
platelet aggregation as measured by multiple platelet aggregometry 
 
To evaluate the method, we measured spontaneous platelet aggregation, 
platelet aggregation induced by a „weak” platelet agonist ADP, and two „strong” 
platelet agonists, collagen and the PAR1 receptor agonist TRAP-6. In multiple 
platelet aggregometry a small, but considerable amount of spontaneous platelet 
aggregation was found, which ranged from 0-123 AU*min during the 
measurements. However, when turbulent stirring was applied (alternate movement 
of the stirrer to right and left by 180°, as described above) spontaneous aggregation 
was much higher (280±108 AU*min, mean±SD, n=6 in hirudin-anticoagulated 
blood) as compared to normal, circular stirring (37± 23 AU*min, mean±SD, n=8, 
p<0.05) (Figure 2.5.).  
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Figure 2.5. The effect of turbulent stirring on spontaneous platelet aggregation. 
Spontaneous platelet aggregation was measured in hirudin-anticoagulated blood 
while being stirred turbulently (the stirrer was turned alternately to the right and left 
by 180°) and normally for 5 minutes in a Multiplate® test cell. Data are mean±SD 
(n=6). Asterisks indicate statistical significance (p<0.05). 
 
 
ADP induced a moderate platelet aggregation in anticoagulated whole blood 
in a time- and dose-dependent manner (Figure 2.6. A). Maximal platelet 
aggregation induced by ADP was highly variable between different donors (Figure 
2.7. A, B), it ranged from 27 AU*min to 900 AU*min. When ADP-induced platelet 
aggregation was assessed for the same two donors on different days over a time 
period of 4 months, platelet aggregation was fairly constant. For donor “A” it 
ranged from 276 to 435 AU*min (365±68, mean±SD, n=5, CV: 18%), and for 
donor “B” it ranged from 413 to 483 AU*min (448±49, mean±SD, n=3, CV: 11%). 
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Figure 2.6. Kinetic of platelet aggregation induced by ADP (A), collagen (B) and 
TRAP-6 (C) measured by MEA. Each measurement by MEA results in two 
independent aggregation curves measured by duplicate sensors located in each 
test cell. Data are representative of at least 5 experiments. 
 
 
Collagen induced platelet aggregation obtained with impedance 
aggregometry started after a timelag, which changed in a dose- and donor-
dependent manner (Figure 2.6. B). The maximal aggregation induced by collagen 
(2.5 µg/ml) in citrate- and hirudin-anticoagulated blood varied between different 
donors (Figure 2.7. C, D). It ranged from 225 to 899 AU*min. Maximal aggregation 
after collagen-stimulation varied less than after ADP stimulation of blood (compare 
with Figure 2.7. A, B).  
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Figure 2.7. Distribution of ADP- and collagen-induced platelet aggregation 
measured by MEA. Platelet aggregation induced by 5 µmol/l ADP in citrated (A) or 
in hirudin-anticoagulated blood (B), and 2.5 µg/ml collagen in citrated (C) or in 
hirudin-anticoagulated blood (D) of 29, 21, 20 and 18 different healthy donors, 
respectively, assessed by multiple electrode aggregometry. 
 
 
With phase contrast microscopy we observed that while collagen resulted in 
a higher platelet aggregation signal than ADP when measured by MEA, it induced 
more platelet layers to adhere to the electrodes than ADP (Figure 2.8.). Platelet 
aggregates could be seen only on one side of the electrode. In the case of 
spontaneous platelet aggregation we saw no apparent platelet aggregation using 
phase contrast microscopy, whereas using fluorescence microscopy some adhered 
platelets and red blood cells could be recognised on the surface of the electrode (not 
shown).  
 ADP                                                     collagen 
citrate                  hirudin                        citrate                  hirudin  
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Figure 2.8. Phase contrast microscopy of three cut Multiplate® electrodes. A 
represents an electrode after a 5 minute run without agonist (control), B ADP (5 
µmol/l) - induced platelet aggregation, and C collagen (2,5 µg/ml) – induced 
platelet aggregation.  
 
TRAP-6-induced platelet aggregation was characterized by a rapid initial 
response without a lag phase and a rapidly reached maximal aggregation (Figure 
2.6. C). The maximal aggregation induced by TRAP-6 (20 µmol/l) in citrate- and 
hirudin anticoagulated blood varied between different donors and ranged from 230 
to 1028 AU*min. The interindividual variation of aggregation was less after TRAP 
stimulation than after stimulation with ADP (data not shown). 
When measured by MEA, spontaneous platelet aggregation did not correlate 
with stimulus-induced platelet aggregation of citrate- or hirudin- anticoagulated 
blood. ADP-, collagen- and TRAP-6-induced maximal platelet aggregation showed 
a linear correlation with each other in blood anticoagulated with citrate or hirudin 
(Figure 2.9. and data not shown). The half maximal effective concentrations for 
ADP, collagen and TRAP-6 are represented in Table 2.1. (page 26.). 
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Figure 2.9. Correlation between collagen- and ADP-induced maximal platelet 
aggregation (PA). Platelet aggregation induced by 5 µmol/l ADP or 2.5 µg/ml 
collagen was measured by multiple electrode aggregometry in citrated blood 
(n=17). Statistical analysis was performed by linear regression analysis. 
 
 
2.4.2. Effect of different anticoagulation techniques 
 
Citrate, the most commonly used anticoagulant in haemostasis 
measurements, complexes divalent cations, lowering the millimolar concentration 
of ionized calcium into the micromolar range (less than 5 µmol/l) [64]. Calcium is 
an important participant in coagulation, and it may also affect platelet aggregation. 
Hirudin, which prevents clotting by inhibiting the action of thrombin, has the 
advantage of preserving the physiological concentration of ionized calcium and 
magnesium [65,66]. Thus to investigate the effect of anticoagulation, we measured 
platelet aggregation parallelly in both citrate- and hirudin-anticoagulated whole 
blood. We found differences in spontaneous aggregation, agonist-induced platelet 
aggregation, and also the effect of different inhibitors.  
Spontaneous platelet aggregation was higher in citrated blood than in 
hirudin-anticoagulated blood. In hirudin-anticoagulated blood, but not in citrated 
blood, pre-treatment with apyrase significantly reduced spontaneous platelet 
aggregation. Aspirin had no effect on spontaneous platelet aggregation when either 
anticoagulants were used (Figure 2.10).  
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Figure 2.10. Effects of anticoagulation and inhibition by apyrase and aspirin on 
spontaneous platelet aggregation. Spontaneous platelet aggregation measured by 
multiple electrode aggregometry in citrated (open bars) or hirudin-anticoagulated 
blood (closed bars) after 5 minutes of stirring. Data are mean±SD (n=8). Asterisk 
indicates statistical significance of the effects of apyrase (10 U/ml, APY) or aspirin 
(1 mmol/l, ASA) as compared to control (*p<0.05). Cross indicates statistical 
significance of the difference between citrated and hirudin-anticoagulated blood 
(p<0.05). 
 
In the case of agonist-induced platelet aggregation we observed that all 
agonists induced higher aggregation in hirudin-anticoagulated blood as compared to 
citrated blood. Maximal platelet aggregation induced by ADP was lower in citrated 
blood (304±136 AU*min) than in hirudin-anticoagulated blood (483±224 AU*min, 
mean±SD; n=20; p<0.00001) (Figure 2.7. A, B). Figure 2.11. shows that this 
difference could be observed for all ADP concentrations used, but was not apparent 
when measured by single platelet counting. 
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Figure 2.11. ADP-induced platelet aggregation in citrate and hirudin-anticoagulated 
blood. Dose – response curves of ADP assessed by multiple electrode aggregometry 
(A) and single platelet counting (B). Data are mean±SD (n=5). Asterisks indicate 
statistical significance of the difference between hirudin- and citrate- anticoagulated 
blood (*p<0.05). 
 
The maximal aggregation induced by collagen was again lower in citrate- 
than in hirudin-anticoagulated blood (Figure 2.7. C, D). The values (mean±SD) 
were 421±128 AU*min and 674±110 AU*min, respectively (p<0.00001, n=19, see 
also Figure 2.15. C, D). The EC50 of collagen was lower in citrated than in hirudin-
anticoagulated blood, indicating that the platelets were more, rather than less, 
sensitive to collagen-stimulation in citrate- blood as compared with hirudin-blood  
(Table 2.1., p<0.01). TRAP-6-induced platelet aggregation was higher in hirudin-
anticoagulated blood than in citrated blood measured by MEA. The mean±SD was 
691±184 AU*min and 531±194 AU*min in hirudin- and citrate-anticoagulated 
blood, respectively (p<0.0001, n=15).  
 
2.4.3. Comparison of multiple electrode aggregometry and single platelet counting 
 
Spontaneous platelet aggregation during stirring of diluted whole blood was 
observed by both single platelet counting (Figure 2.12.) and MEA (Figure 2.10.). 
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Figure 2.12. Spontaneous platelet aggregation in whole blood assessed by single 
platelet counting was not significantly affected by apyrase (10 U/ml, APY), aspirin 
(1mmol/l, ASA) or the type of anticoagulation used (citrated blood: open bars, 
hirudin-anticoagulated blood: closed bars). Data are mean±SD (n=8).  
 
By comparing the time-course of ADP-induced platelet aggregation 
measured by single platelet counting or MEA, it was observed that maximal platelet 
aggregation was reached more rapidly according to single platelet counting. Also, 
platelet aggregation induced by 1 µmol/l ADP was partly reversible according to 
single platelet counting (Figure 2.13), which was not observed with MEA (Figure 
2.6. B).  
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Figure 2.13. Time course of ADP induced platelet aggregation measured by single 
platelet counting. Data are representative of 5 experiments. 
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The dose-response curves for ADP were similar in both methods (Figure 
2.11). However the EC50 of ADP measured by single platelet counting tended to be 
lower than when measured by MEA (Table 2.1).  
 
Table 2.1. Half maximal effective concentrations (EC50) of different agonists for 
platelet aggregation measured by single platelet counting (SPC) or multiple 
electrode aggregometry (MEA) in citrate- or hirudin-anticoagulated blood. 
 
  ADP (µmol/l) Collagen (µg/ml) TRAP (µmol/l) 
    EC50 p EC50 p EC50 p 
            
Citrate 
SPC 0.98±0.58 (4) 
0.051 
0.13±0.03 (4) 
0.011 
3.28±0.26 (4) 
0.85 
MEA 1.57±0.80 (4) 0.33±0.08 (4) 3.43±1.28 (4) 
                
            
Hirudin 
SPC 0.70±0.21 (4) 
0.325 
0.16±0.04 (4) 
0.018 
5.10±2.33 (5) 
0.36 
MEA 1.00±0.56 (4) 0.63±0.17 (4) 4.48±2.49 (5) 
                
Note: Data are mean±SD (n in parenthesis). The statistical significance (p-values) 
was assessed between the data of single platelet counting and MEA.  
 
The collagen dose-response curves were different in both methods of 
aggregation measurement (see also Figure 2.15, page 34.). The half maximal 
effective concentration (EC50) of collagen to induce platelet aggregation was 
significantly lower when aggregation was measured by single platelet counting as 
compared to MEA, both in citrate- and hirudin-anticoagulated blood (Table 2.1.). 
TRAP-6, as a strong platelet aggregation-inducing agent, caused irreversible 
aggregation at all examined concentrations as measured by MEA. The dose-
response curves of TRAP-6 were similar in both methods of aggregation 
measurement (see also Figure 2.16.) shown by comparison of the EC50 values 
(Table 2.1.). No significant effect of the type of anticoagulation was found when 
ADP-, collagen-, or TRAP-6-induced maximal platelet aggregation was assessed by 
single platelet counting. 
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2.4.4. Evaluation of the in vitro platelet aggregation inhibitory effects of aspirin and 
apyrase  
 
In clinical settings, the two most commonly used platelet aggregation 
inhibitors target the cyclooxygenase-1 (COX1) enzyme and the ADP receptor 
P2Y12. We used the COX inhibitor aspirin and the ADP scavenger enzyme apyrase 
in vitro to test MEA’s ability to detect their action in comparison with single 
platelet counting.  
As already mentioned above, spontaneous platelet aggregation was 
significantly reduced by pre-treatment with apyrase, but not with aspirin in hirudin-
anticoagulated blood. No effect of apyrase or aspirin on spontaneous platelet 
aggregation measured by MEA in citrated blood or by single platelet counting in 
citrated or hirudin-anticoagulated blood was found (Figure 2.10. and Figure 2.12.).  
On the other hand, when turbulent stirring was applied (alternate movement 
of the stirrer to right and left by 180°) the high spontaneous platelet aggregation 
could be reduced by aspirin and by apyrase which indicates a role of TxA2 released 
from activated platelets and ADP released from activated platelets and/or damaged 
red blood cells (Figure 2.14.).  
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Figure 2.14. Effects of apyrase (10 U/ml, APY) and aspirin (1mmol/l, ASA) on 
spontaneous platelet aggregation induced by turbulent stirring. Spontaneous platelet 
aggregation was measured in hirudin-anticoagulated blood while being stirred 
turbulently (the stirrer was turned alternately to the right and left by 180°) for 5 
minutes in a Multiplate® test cell. Data are mean±SD (n=6). Asterisks indicate 
statistical significance of the effects of apyrase (10 U/ml, APY) or aspirin (1 
mmol/l, ASA) as compared to control (*p<0.05).  
 
 
 
The collagen-induced platelet aggregation measured by single platelet counting or 
MEA was partially inhibited by the ADP scavenger enzyme apyrase (10 U/ml) and 
aspirin (1 mmol/l). The inhibitory effect of aspirin was more pronounced when 
aggregation was measured by MEA in comparison to single platelet counting. 
Inhibition by apyrase was most pronounced in hirudin-anticoagulated blood when 
aggregation was measured by MEA (Figure 2.15.).  
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Figure 2.15. Collagen-induced platelet aggregation in citrate- (A, C) or hirudin- (B, 
D) anticoagulated blood. Dose – response curves of collagen assessed by SPC (A, 
B) or MEA (C, D). Data are mean±SD (n=4). Asterisks indicate the statistical 
significance of the effect of 10 U/ml apyrase (APY) or 1 mmol/l aspirin (ASA) 
(*p<0.05 or ‡p<0.01). 
 
 
Aspirin did not inhibit TRAP-6-induced platelet aggregation according to 
single platelet counting or MEA in citrate- or in hirudin-anticoagulated blood. 
Apyrase slightly inhibited platelet aggregation at various TRAP-6 concentrations in 
both single platelet counting and MEA (Figure 2.16.).  
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Figure 2.16. TRAP-6 induced platelet aggregation in citrate- (A,C) or hirudin- 
(B,D) anticoagulated blood. Dose – response curves of TRAP-6 assessed by SPC 
(A,B) or MEA (C,D). Data are mean±SD (n=4). Asterisks indicate the statistical 
significance of the effect of 10 U/ml apyrase (APY) (*p<0.05). 
 
 
2.4.5. Investigating the contribution of the two platelet ADP receptors (P2Y1 and 
P2Y12) in platelet aggregation 
 
2.4.5.1. Evaluation of the effective inhibitory concentrations of the ADP receptor 
antagonists MRS2179 and AR-C69931MX on ADP-induced platelet aggregation 
 
ADP-induced platelet aggregation measured by MEA was concentration 
dependently inhibited by the ADP receptor P2Y1 inhibitor MRS2179 and the P2Y12 
inhibitor AR-C69931MX. The aggregation was completely inhibited by certain 
concentrations of the antagonists (>100 µmol/l MRS2179 and >100 nmol/l AR-
C69931MX) (Figure 2.17.).  
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Figure 2.17.  Concentration dependency of inhibition of ADP (5 µmol/l) -induced 
platelet aggregation by AR-C66931MX (A) or MRS2179 (B) measured by multiple 
electrode aggregometry in hirudin-anticoagulated whole blood. Control represents 
spontaneous platelet aggregation without an added inhibitor. Data are representative 
of at least 5 experiments. 
 
 
We determined the half maximal effective inhibitory concentrations (IC50) 
of platelet aggregation induced by 5 µmol/l ADP of the antagonists using different 
anticoagulation techniques. The IC50 values for AR-C69931MX were 3 nmol/l in 
hirudin-anticoagulated blood and 4 nmol/l in citrated blood, while for MRS2179 
they were 1.5 µmol/l in hirudin-anticoagulated blood and 6 µmol/l in citrated blood 
(Figure 2.18).  
Very low concentrations of MRS2179 (0.1 µmol/l) seemed to enhance 
platelet aggregation to some extent (by 20%). Based on these findings 1 µmol/l or 
(in case of the ex vivo experiments) 100 nmol/l concentration of AR-C69931MX 
and 100 µmol/l of MRS2179 were chosen in order to evaluate the role of the ADP 
receptors in spontaneous platelet aggregation or platelet aggregation induced by 
different agonists. 
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Figure 2.18. Inhibition of platelet aggregation induced by 5 µmol/l ADP by AR-
C69931MX (empty squares) and MRS2179 (diamonds) in citrate- (A) and hirudin-
anticoagulated (B) blood. Data are mean±SD (n=5).   
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2.4.5.2. Inhibition of spontaneous platelet aggregation by MRS2179 and AR-
C69931MX   
 
The spontaneous platelet aggregation as measured by MEA was 
significantly inhibited by both ADP receptor antagonists in hirudin-anticoagulated 
blood; there was no detectable additive effect between the two antagonists when 
added together. Spontaneous platelet aggregation was 44.9 AU*min, 17.0 AU*min, 
15.2 AU*min and 13.9 AU*min for control, with the addition of 1 µmol/l AR-
C69931MX, 100 µmol/l MRS2921, or both, respectively (results are mean ± SD). 
These results indicate that spontaneous platelet aggregation by trace amounts of 
ADP in stirred hirudin-blood is mediated by activation of both the P2Y1 and P2Y12 
receptor.  
In citrated blood, however, only the P2Y1 antagonist MRS2179 had 
statistically significant inhibitory effect (it reduced spontaneous platelet aggregation 
by 40%) (Figure 2.19), indicating that only P2Y1 activation is required. 
Spontaneous platelet aggregation was 36.2 AU*min for control, 32.4 AU*min, 21.7 
AU*min and 18.9 AU*min, with the addition of 1 µmol/l AR-C69931MX, 100 
µmol/l MRS2921, or both, respectively (results are mean ± SD). 
 
 
 
 
 
 
 
 
 
Figure 2.19. Effects of AR-C69931MX (1 µmol/l, ARC) and MRS2179 (100 
µmol/l, MRS) on spontaneous platelet aggregation in citrate- (open bars) or hirudin-
anticoagulated blood (closed bars). Data are mean±SD (n=9). Asterisks indicate 
statistical significance of the effects of AR-C69931MX or MRS2179 (*p<0.05) as 
compared to control. 
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2.4.5.3. Inhibition of collagen–induced platelet aggregation by MRS2179 and AR-
C69931MX   
 
Both ADP receptor antagonists showed approximately the same effect if 
hirudin anticoagulation was used. MRS2179 (100 µmol/l) inhibited platelet 
aggregation induced by collagen (0.5-1-2.5 µg/ml) by 71.6-49.1-39.8 (8.1-24.9-
17.3) %, respectively and AR-C69931MX (1 µmol/l) by 62.0-55-30 (20.8-10.7-9.9) 
%, respectively (data are mean (SD)).  MRS2179 had less effect in citrated blood, 
which difference was statistically significant, when aggregation was induced by 1 or 
2.5 µg/ml collagen. The combination of both antagonists showed synergism in 
inhibition of collagen induced platelet aggregation (Figure 2.20.). 
If we relate all aggregation data to the collagen-induced platelet aggregation 
achieved in hirudin blood without adding an antagonist (100%), it is apparent that 
the relative amount of the residual platelet aggregation was about the same in 
citrated and hirudin-anticoagulated blood after adding an ADP receptor antagonist, 
and this reduction was enhanced when they were added together (Figure 2.21.) 
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Figure 2.20. Effects of MRS2179 (100 µmol/l, MRS) and AR-C69931MX (1 
µmol/l, ARC) on platelet aggregation induced by collagen (0,1-2,5 µg/ml) in 
citrate- (a) or hirudin-anticoagulated blood (b). Data are mean±SD (n=5). Symbols 
indicate statistical significance of the effects of AR-C69931MX or MRS2179 
(*p<0.05) as compared to control, or interaction between AR-C69931MX or 
MRS2179 (‡p<0.05). 
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Figure 2.21. Inhibitory effect of MRS2179 (100 µmol/l, MRS) and AR-C69931MX 
(1 µmol/l, ARC) on platelet aggregation induced by 0.5 µg/ml collagen in citrate- 
(open bars) or hirudin-anticoagulated blood (closed bars) as related to the 
aggregation induced by 0.5 µg/ml collagen in hirudin-anticoagulated blood without 
added antagonists. Data are mean±SD (n=5). Symbol indicates statistical 
significance (*p<0.05) between the two different anticoagulants.  
 
 
2.4.5.4. Inhibition of TRAP-6-induced platelet aggregation by MRS2179 and AR-
C69931MX   
 
There was a clear inhibition of AR-C69931MX in both anticoagulants used 
on TRAP-6-induced platelet aggregation, to about 25-80% of control aggregation. 
The higher the TRAP-6 concentrations, the less inhibition of aggregation could be 
achieved with AR-C69931MX. MRS2179, however did not inhibit the TRAP-6-
induced platelet aggregation in citrated blood, on the other hand, it significantly 
enhanced the aggregation induced by 10 µmol/l TRAP-6 (Figure 2.22. A). In 
hirudin-anticoagulated blood however, MRS2179 was able to inhibit 3.75 µmol/l 
TRAP-6-induced platelet aggregation to the same extent as AR-C69931MX, but 
this inhibitory potential declined with the increase in the TRAP-6 concentration. 
Despite of the loss of the inhibitory effect of MRS2179, a synergism between the 
antagonists could be observed even at higher TRAP-6 concentrations (Figure 2.22. 
B). 
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Figure 2.22. Effects of MRS2179 (100 µmol/l, MRS) and AR-C69931MX (1 
µmol/l, ARC) on platelet aggregation induced by TRAP-6 (2,5-20 µmol/l) in 
citrate- (A) or hirudin-anticoagulated (B) blood. Data are mean±SD (n=4). Symbols 
indicate statistical significance of the effects of AR-C69931MX or MRS2179 
(*p<0.05) as compared to control, or interaction between AR-C69931MX and 
MRS2179 (‡p<0.05). 
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2.4.6. Clopidogrel responsiveness measured by MEA in blood (ex vivo studies)  
 
Control ("spontaneous") platelet aggregation seemed not to be affected by 
clopidogrel intake. Inhibition of ADP (5 µmol/l)-induced platelet aggregation 3h to 
3 days after clopidogrel intake was dependent on the volunteer tested (Figure 2.23.). 
In hirudin-anticoagulated blood, 2 persons (P1 and P2) showed more than 90% 
inhibition of aggregation (clopidogrel responsive), whereas 2 persons (P3, P5) were 
clopidogrel-resistant (<10% inhibition). Two persons (P4, P6) were partially 
responsive to clopidogrel (49 and 57 % inhibition). The maximal effect could be 
seen already 3 hours after the administration of the loading dose (300 mg) of 
clopidogrel, and the effect was fairly constant throughout the experiment. Addition 
of AR-C69931MX (100 nmol/l) to the test cells in vitro maximally inhibited ADP-
induced platelet aggregation before and after clopidogrel-intake in all volunteers, 
thereby indicating the functional P2Y12 receptor reserve after clopidogrel-intake 
(i.e. clopidogrel could not inhibit platelet aggregation completely). Similar 
observations were made, when citrate was used as anticoagulant. However, ADP-
induced aggregation was again lower in citrate- than in hirudin-anticoagulated 
blood, and the inhibition by clopidogrel was therefore less detectable (data not 
shown).   
Addition of PGE1 (10 nmol/l in case of hirudin anticoagulated blood, 6 
nmol/l in case of citrated blood) itself inhibited platelet aggregation by 30-50%, and 
enhanced the clopidogrel induced platelet inhibition from ~40% to ~60-85% in 
hirudin blood. Except of P1 and P2, whose ADP-induced platelet aggregation was 
completely inhibited by clopidogrel, the relative inhibition was higher when using 
additional PGE1 than ADP alone (Figure 2.24. and Figure 2.23). 
As expected from the results of incomplete inhibition of TRAP- and 
collagen -induced platelet aggregation by AR-C69931MX, TRAP-6 and collagen-
induced aggregation was only slightly affected after clopidogrel intake. Collagen-
induced platelet aggregation remained practically unchanged after clopidogrel 
intake (data not shown). Two weeks after the last clopidogrel intake, aggregation 
values returned to the previous levels (Figure 2.24.). 
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Figure 2.23. Effects of per os clopidogrel treatment, in vitro added PGE1 and AR-
C69931MX (100 nmol/l, ARC) on platelet aggregation induced by ADP (5 µmol/l) 
in hirudin-anticoagulated blood on 6 healthy individuals. Lines and symbols 
indicate the inhibitory rate (%) of clopidogrel with (□) or without (▲) the addition 
of PGE1 related to the platelet aggregation at time point 0 (100%) with (□) or 
without (▲) the addition of PGE1, respectively.  
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Figure 2.24. Effects of per os clopidogrel treatment and in vitro added PGE1 and 
AR-C69931MX (100 nmol/l, ARC) on platelet aggregation induced by ADP (5 
µmol/l) in citrate (A) and hirudin-(B) anticoagulated blood of 6 healthy individuals. 
Data are mean±SD (n=6). Symbols indicate statistical significance of the effects of 
clopidogrel (*p<0.05) as compared to the aggregation before clopidogrel intake, or 
the effect of PGE1 or AR-C69931MX (‡p<0.05). 
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2.5. Discussion 
 
We were the first to introduce a new technique for whole blood 
aggregometry based on the impedance method. The new method applies duplicate 
impedance sensors each consisting of two straight electrode wires. Based on the 
application of a total of 4 electrodes for the analysis, the method is called “multiple 
electrode aggregometry” (MEA). By the application of an electrical signal, the 
measurement is independent of optical variables in the sample (e.g. lipemia) [62]. 
Each analysis provides a kinetic signal which is characterized by the area under the 
curve (AUC, expressed as AU*min). We found that the instrument was easy to 
handle and the results were highly reproducible.  
In whole blood aggregometry, unlike light transmission aggregometry, there 
is no possibility to adjust the platelet concentration. Therefore we investigated the 
correlation between whole blood platelet concentration and the maximal 
aggregation responses to different agonists. Previously, Sharp et al. showed a strong 
correlation between whole blood platelet count and ADP-induced platelet 
impedance changes [67]. Our data, however, did not show a dependency of the 
aggregation induced by collagen, ADP and TRAP on the platelet concentrations 
within the normal range of platelet counts in healthy volunteers (Figure 2.4.). 
According to our observations with phase contrast microscopy, the greater amount 
of platelets aggregated on the surface of the electrode, the higher signal was 
detected by the instrument. 
We observed a great interindividual variability in both spontaneous and 
agonist-induced platelet aggregation when measured by MEA, and the variability of 
platelet aggregation was most pronounced after stimulation with ADP. A linear 
correlation was shown between the aggregations induced by different agonists. No 
correlation was observed, however, between spontaneous platelet aggregation and 
stimulated platelet aggregation.  
All of the investigated agonists elicited significantly higher platelet 
aggregation responses measured by MEA in hirudin-anticoagulated blood than in 
citrated blood, confirming previous findings of Wallén et al. [64]. Interestingly, 
spontaneous platelet aggregation according to MEA was less in hirudin-blood than 
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in citrated blood (7% vs. 16% of maximal aggregation, respectively), which 
excludes the possibility of an artefact caused by hirudin. However, since 
spontaneous aggregation was not inhibited in citrated blood by apyrase or by 
aspirin, consequently neither ADP nor TXA2 contributed to the more pronounced 
spontaneous aggregation. The higher spontaneous aggregation in citrate-
anticoagulated vs. hirudin-anticoagulated blood could be explained by small traces 
of active thrombin possibly present in blood anticoagulated with citrate. 
MEA was compared to single platelet counting, one of the standard 
techniques of platelet aggregation analysis in whole blood. We found that the 
results obtained by MEA compared, in general, well with the single platelet 
counting method in diluted blood.  
Some spontaneous platelet aggregation by stirring of diluted whole blood 
was observed using both single platelet counting and MEA. Armstrong et al. 
reported spontaneous aggregation determined by single platelet counting which was 
inhibited by the membrane stabilizer chlorpromazine [68]. In our experiments, 
spontaneous aggregation determined by single platelet counting was not 
significantly inhibited by apyrase or aspirin. In hirudin-blood spontaneous platelet 
aggregation was significantly inhibited by apyrase when measured by MEA, which 
suggests a role of ADP that could be released either from red blood cells or 
platelets. We found that the use of a different MEA instrument causing more 
turbulence due to uneven stirring resulted in significantly higher spontaneous 
platelet aggregation. This can be explained by both the release of ADP and the 
formation of TxA2 from activated platelets, since under these conditions 
spontaneous aggregation could be inhibited by both apyrase and aspirin. 
Besides the good agreement of platelet aggregation responses determined by 
SPC and MEA, differences between the two methods were also observed. Single 
platelet counting was more sensitive in the detection of platelet aggregation induced 
by low concentrations of ADP (non-significant) and collagen (significant), while 
there was no difference in sensitivity towards TRAP-6-induced platelet aggregation. 
These differences are probably due to the fact that single platelet counting method 
measures recruitment of platelets into platelet aggregates which can be as small as 
two platelets, while impedance aggregometry is dependent on firm attachment of 
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platelets onto the metal sensors. Accordingly, platelet aggregation measured by the 
single platelet counting method was more rapid than when measured by MEA. The 
reversible phase of aggregation induced by ADP was not detectable by impedance 
aggregometry. However, the normal blood cation concentration seems to be 
important for platelet spreading and platelet aggregation as measured by impedance 
aggregometry, since the ADP-, collagen- and TRAP-induced platelet aggregation 
was lower in citrate-anticoagulated blood when measured by MEA, but it did not 
affect platelet aggregation measured by SPC.   
The sensitivity of impedance aggregometry towards low dosages of aspirin 
has previously been shown by Sathiropas et al. [69] in ex vivo experiments. Riess et 
al. showed that the anti-platelet effect of a single oral dose of aspirin on collagen-
induced platelet aggregation could be detected for a longer period by impedance 
aggregometry than by the turbidimetric method [61]. In the MEA device, aspirin 
had a significant inhibitory effect even at the highest concentration of collagen used 
(2.5 µg/ml) in contrast to inhibition measured by single platelet counting. Using 
impedance aggregometry Wallén et al. also found that inhibition of platelet 
aggregation by aspirin was more pronounced in citrated blood compared to hirudin 
treated blood [64]. However, this could not be confirmed by our study.  
When comparing platelet inhibition of the ADP scavenger apyrase in citrate- 
and hirudin-anticoagulated blood, we found that inhibition - as measured by both 
methods - was more pronounced in hirudin-anticoagulated blood. These findings 
are in accordance with the observations of Storey et al. on the effects of ADP 
receptor antagonists in hirudin-anticoagulated blood measured by single platelet 
counting [70]. 
Adenosine diphosphate is generally known as a week agonist of platelet 
aggregation. However, it plays an important role in the amplification of platelet 
aggregation induced by several “strong” agonists. ADP binds to two G-protein-
coupled purinoceptors on platelet surface, the ADP receptor P2Y1 and P2Y12. The 
P2Y1 is linked to a Gq protein, and its activation leads to the activation of 
phospholipase-C (PLC), and this accounts for most of the elevation in cytosolic 
Ca2+ induced by ADP, via formation of inositol triphosphate (IP3) and release of 
Ca2+ from intracellular stores [71,72]. This receptor was formerly known to initiate 
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the platelet aggregation induced by ADP [73,74]. Jin and Kunapuli demonstrated 
that also the Gi protein P2Y12 is needed for platelet aggregation, reducing cyclic 
AMP levels via inhibition of adenylate cyclase [75].  
The fact that the ADP scavenger enzyme apyrase inhibited the spontaneous, 
collagen-induced, as well as TRAP-6-induced platelet aggregation proves the role 
of ADP released during platelet activation. Hence we investigated the role of the 
two platelet ADP receptors, P2Y1 and P2Y12 in the contribution of the effect of 
released ADP.  
Aleil et al. showed, that inhibition of P2Y12 receptor in citrate-PRP results in 
a decreased, reversible platelet aggregation when measured by turbidimetric 
method, which cannot be diminished by increasing the antagonist concentration 
[76]. Storey at al. however reported that the potent P2Y12 receptor inhibitor AR-
C69931MX (now in phase III drug developing studies known as cangrelol) in the 
same concentration completely blocked platelet aggregation, when measured by 
turbidimetry, while in single platelet counting a transient, reversible aggregation 
could be observed [77]. However, they used hirudin anticoagulation, which may be 
an explanation for the difference, as it is known, that low divalent cation 
concentration enhances the release reaction in citrated blood [78]. MRS2179 
abolished platelet aggregation using either of the methods, when hirudin 
anticoagulation was used.  
When determining the effective concentrations of the ADP receptor 
antagonists on ADP induced platelet aggregation by MEA, regardless of the 
anticoagulation used, we did not observe this reversible phase of aggregation and at 
a certain AR-C69931MX concentration the aggregation was completely inhibited. 
The same was observed when using MRS2179. These findings suggest that 
activation of both receptors is essential to the firm attachment of platelets to the 
MEA electrodes, and perhaps therefore to other non-physiological surfaces such as 
atherosclerotic plaques.  
The inhibitory effect of the used antagonists was concentration dependent, in 
accordance with findings observed by turbidimetry or VASP phosphorilation [76], 
single platelet counting [77], PAC-1 expression assessed by whole blood flow 
cytometry [79]. IC50 values of AR-C69931MX were similar in hirudin- and citrate-
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anticoagulated blood, whereas MRS2179 was more effective in hirudin-
anticoagulated blood. This finding suggests that in citrated blood, the P2Y1 receptor 
or its transduction pathways are already impaired probably due to the low cation 
concentration.  
We have shown that spontaneous platelet aggregation was inhibited by 
apyrase only in hirudin-anticoagulated blood. Additionally we observed that both 
ADP receptor antagonists inhibited spontaneous platelet aggregation in hirudin 
anticoagulated blood. Surprisingly, spontaneous platelet aggregation was inhibited 
by MRS2179 also in citrated blood, despite MRS2179 being more effective in 
hirudin blood. 
Both ADP receptor antagonists inhibited collagen induced platelet 
aggregation, suggesting that the secondarily released ADP is important in collagen 
induced platelet aggregation. Penz et al. demonstrated that collagen structures in 
human atheromatous plaques play a central role in thrombus formation by 
activating the platelet glycoprotein VI (GP VI) [80]. According to the current 
models, the binding of collagen to GP VI results in the activation of phospholipase 
C γ2 isoform (PLCγ2) and a raise in the free cytosolic Ca++ concentration and the 
activation of protein kinase C (PKC) [81]. The activation does not directly involve 
Gαq or Gαi activation, but results in release reaction, and activation of other cell- 
surface receptors, including integrin αIIbβ3 and α2β1 due to inside-out signalling. It 
is also known, that only a small portion of platelets are directly activated by 
collagen, even at high collagen concentration, probably because of its bulky nature. 
Thus the secondarily released agonists play an important role in collagen-induced 
platelet aggregation.  
The effect of the two antagonists was inversely proportional to the collagen 
concentration, suggesting that the released ADP has more importance at low 
collagen concentrations, but at higher collagen concentrations other mechanisms 
come to the front, although even at 2.5 µg/ml collagen both antagonists still had a 
significant inhibitory effect on platelet aggregation measured by MEA. Compared 
to single platelet counting, multiple electrode aggregometry appears to be more 
sensitive to detect the ADP receptor inhibition, since Storey et al. used the same 
type of collagen (Horm) to demonstrate the effect of AR-C69931MX and MRS2179 
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on collagen-induced platelet aggregation as measured by single platelet counting, 
and in hirudin anticoagulated blood there was no inhibitory effect of the ADP 
receptor antagonists at 2 µg/ml collagen [70]. 
We observed that MRS2179 had a markedly lesser effect in citrated blood 
than in hirudin blood, but the overall residual platelet aggregation was about the 
same in both anticoagulants. On the other hand, the platelet aggregation obtained in 
citrated blood was decreased related to the aggregation obtained in hirudin-
anticoagulated blood. These findings suggest that this decrease in aggregation is due 
to the impairment of a P2Y1 dependent pathway because of the not physiological 
divalent cation concentrations in citrated blood. As this effect could not be detected 
in citrated blood before by single platelet counting (measuring microaggregation), 
we suppose, that the P2Y1 receptor dependent pathway is responsible for 
macroaggregate formation, thus the formation of large, stable haemostatic 
aggregates in vivo, which are essential for haemostasis by strong platelet plugs, 
paving the way for clot retraction [82].   
TRAP-6 is a synthetic peptide ligand of the thrombin-receptor PAR-1, a 
member of the G-protein coupled receptors found on platelets. We found, that 
TRAP-6 induced platelet aggregation can be partially inhibited by P2Y12 receptor 
blockade; however, the P2Y1 inhibitor MRS2179 has little effect on platelet 
aggregation. These findings are consistant with the fact, that activated PAR-1 
directly activates Gαq protein, and secondarily enhances the release reaction. The 
released ADP promotes the platelet aggregation mainly due to the P2Y12 receptor, 
since the P2Y1 receptor-linked Gαq is already activated. The effect of the 
antagonists, just like at collagen-induced aggregation, was inversely proportional to 
the TRAP-6 concentration, suggesting that the released ADP is of greater 
importance at low TRAP-6 concentrations. This is in accordance with the findings 
of Nylander et al., who investigated platelet inhibition by single platelet counting 
and by the platelet activation marker PAC-1 expression (antibody recognizing the 
active conformation of αIIBβ3) with flow cytometry [79].  
In hirudin anticoagulated blood, however, when inducing platelet 
aggregation with low TRAP-6 concentrations we observed marked inhibition by 
MRS2179. One possible explanation for this is that so low TRAP-6 concentrations 
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do not completely activate Gαq, thus released ADP can activate the other part. 
However, this effect could not be observed in citrated blood. 
After we had demonstrated, that MEA had the ability to detect the inhibition 
factor of ADP receptors, we started to investigate the ex vivo platelet aggregation 
inhibitory effect of clopidogrel, which, along with aspirin, is one of the most widely 
used ADP receptor antagonists in the secondary prevention of ACS. Through its 
active metabolites formed in the liver, it irreversibly inhibits the platelet ADP 
receptor P2Y12, resulting in decreased platelet aggregation. In an experiment on a 
small population of healthy individuals we demonstrated, that when measured by 
MEA, the currently clinically recommended clopidogrel dose (saturation dose 
followed by a sustaining dose) significantly decreased the ADP induced platelet 
aggregation as early as three hours after the drug intake. A large variation in the 
extent of decrease could be observed among the volunteers. Amongst our test group 
2/6 persons showed clopidogrel resistance and 4/6 persons had clopidogrel 
responsiveness when we compared inhibition to the platelet aggregation measured 
before clopidogrel intake. This indicates that two of the volunteers were regarded as 
clopidogrel resistant, in two volunteers we detected complete, in other two partial 
inhibitory effects. As we concluded, clopidogrel does not develop a full inhibition 
of the platelet ADP receptor P2Y12, since in vitro added AR-C69931MX could 
increase the inhibitory effect. It has been previously shown, that the effects of 
P2Y12 antagonists are enhanced by natural prostaglandins such as PGE1, as 
prostaglandins increase the intracellular cAMP concentrations and PKA activation, 
thus interfering with P2Y12 receptor activation lowering the cAMP concentration in 
activated platelets [83]. It has also been shown, that VASP phosphorilation was 
more effective in detecting the clopidogrel effect, if ADP was combined with PGE1 
or iloprost [76,84]. In our study, PGE1 generally enhanced the inhibitory effect of 
clopidogrel, as seen in the increased inhibitory rate on Figure 2.23., with the 
exception that the already low platelet aggregation after the addition of PGE1 in P1 
and P2 could not be inhibited in the same proportion, as the other volunteer’s 
platelet aggregation. In short, ADP induced platelet aggregation of hirudin-
anticoagulated blood together with PGE1 proved to be the best combination when 
using multiple electrode aggregometry to detect the clopidogrel effect in healthy 
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volunteers. TRAP-6 or collagen induced platelet aggregation was not suitable for 
recording the clopidogrel effect. To define the limit between responders and non-
responders, larger studies would be required both in healthy populations and among 
ACS patients. In our study, the maximal platelet inhibitory effect of clopidogrel was 
already detectable after 3 hours of drug ingestion, which is in accordance with the 
result of previous studies [85].  
There are some remaining questions. The very high variability among 
individuals raises difficulties in establishing a reference interval for the different 
tests and inhibitions by different drugs. Thus, the extent of inhibition may only be 
calculated if we have values before the inhibiting agent was used. Otherwise, this 
high variability raises the question, whether or not high platelet aggregation also 
observed in a young, healthy group of volunteers reflects high platelet reactivity and 
so acts as a risk factor for ACS or stroke, which may present themselves later in 
their life. Manoharan et al. in a prospective study demonstrated that impedance 
aggregometry is able to distinguish between platelet hypo- and hyperactivity in 
myeloproliferative disorders, which was also beneficial in considering therapeutic 
options [86]. Optical aggregometry has been shown previously to be inadequate in 
detecting platelet hyperactivity [87,88]. These areas also need further investigation.  
Based on our study, several, practically important investigations have been 
made. For example, Sibbing et al. analyzed the platelet reactivity of 149 patients 
scheduled for coronary angiography after clopidogrel treatment, and demonstrated 
that ADP-induced platelet aggregation measured with MEA decreased significantly 
after clopidogrel treatment. Platelet aggregation measured with LTA and 
simultaneously in whole blood with MEA correlated significantly [63]. Afterwards, 
this group demonstrated that patients, who were defined as clopidogrel low 
responders (n = 323) according to their MEA results after a clopidogrel loading 
dose of 600 mg, compared with normal responders (n = 1,285), had a significantly 
higher risk of definite early drug-eluting stent thrombosis within 30 days (2.2% vs. 
0.2%; odds ratio (OR): 9.4; 95% confidence interval (CI): 3.1 to 28.4; p < 0.0001). 
Mortality rates were 1.2% in low versus 0.4% in normal responders (OR: 3.2; 95% 
CI: 0.9 to 11.1; p < 0.07) [89]. 
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In conclusion, by using different agonists we demonstrated that MEA is a 
fast, convenient platelet function testing method that enables the measurement of 
platelet aggregation in diluted whole blood even in point-of-care form. Using 
hirudin for blood anticoagulation proved to be better than citrate. Aggregation 
measurements were convergent to those obtained by single platelet counting. MEA 
was able to detect the inhibitory effect of aspirin, apyrase and ADP receptor 
inhibitors in vitro and also ex vivo at different concentration of agonists, and thus is 
a good candidate for testing even the early effects of antiplatelet drugs in various 
clinical settings.  
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3. The use of rotation thrombelastography in the diagnosis 
of thrombophilia 
 
3.1. Introduction 
 
Citrated plasma has been used predominantly in routine coagulation 
analysis, for several decades. The initial formation of fibrin can easily be detected 
photometrically, and employing activated partial thromboplastin time (APTT) and 
prothrombin time (PT) methodologies, plasma has been widely utilized in the 
diagnosis and monitoring of patients with major coagulation abnormalities. New 
understanding of the biochemistry of physiological haemostasis, in particular the 
tissue factor-dependent generation of thrombin has altered our view of the clotting 
process [90,91]. The importance of thrombin generation patterns in various 
coagulation abnormalities has been established [92,93]. Moreover, a significant role 
of the platelets in promoting thrombin generation has been widely appreciated 
[94,95]. While plasma contains the majority of the coagulation factors implicated in 
the coagulation process, whole blood includes phospholipid bearing cells and 
platelets with an important ability to support coagulation. Recent studies have 
pointed to the importance of the functions of platelets and leukocytes during 
coagulation and fibrinolysis [2,3]. Thus, choosing whole blood for coagulation 
analysis appears more favourable compared to study of plasma coagulation by PT- 
and APTT – based methods that include excessive activation. Furthermore, often 
unphysiological phospholipids are included in the assays to substitute for natural 
cell surface phospholipids. Moreover, since 95% of the coagulation takes place after 
the initiation of clot formation, continuous profiles of coagulation may provide 
additional information on the entire haemostatic process [4,96,97]. 
In 1948, Hartert introduced the trombelastographic principle (TEG) that 
records viscoelastical changes during coagulation [98]. Thrombeleastographic 
analysis of coagulation can be carried out on plasma as well as on whole blood. 
Initially, thrombelastography attracted most interest in research laboratories. 
Although the time course of thrombin generation in plasma and the endogenous 
thrombin potential (ETP) may be useful coagulation parameters, clotting involves 
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components other than thrombin (e.g. platelets, fibrinogen). The continuous 
coagulation profiles of thrombelastography may provide a more accurate reflection 
of in vivo biology, covering initiation, development and final clot strength during 
whole blood clot formation [99]. 
Today, thrombelastography is utilized in various clinical settings, e.g. 
monitoring liver transplantation and cardiac surgery [100], it has also been used to 
investigate hypocoagulation (in haemophilia A [99,101], rare coagulation disorders 
[102], anticoagulant therapy and dilutional coagulopathy [103-105], 
hypercoagulation [106-112] and the ex vivo testing of haemostatic interventions 
[113]. Thrombelastography has been shown to reflect the clinical efficacy of 
activated prothrombin complex concentrate (aPCC) and recombinant activated 
factor VII (rFVIIa) in patients with haemophilia A with inhibitors and in patients 
with acquired haemophilia [101,114]. Although the TEGs ability to detect 
hypercoagulability of whole blood has been proved early and extensively in various 
situations, there are only sporadic reports about the detectability of thrombophilia 
by the method [107,112]. 
Recently a newly developed portable TEG instrument (ROTEG® 
Coagulation Analyzer, Pentapharm Co., Munich, Germany) has been marketed 
[115]. In this TEG, data are continuous, digital, and retrievable for further 
calculations. It proved to be a convenient method for overall patient-near 
haemostatic profiling [116,117]. 
In our study we investigated 55 patients with clinically opposed 
thrombophilia and compared their ROTEG® parameters to those of 66 healthy 
volunteers. Our aims were to investigate the applicability of rotation 
thrombelastography in differentiating between thrombophilia patients and healthy 
subjects, and to differentiate between hereditary and acquired thrombophilias. We 
additionally investigated the effect of LMWH-s and gender on ROTEG® 
parameters.  
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3.2. Aims of the examination of ROTEG® method in various 
thrombophilia conditions  
 
1. Examining the applicability of rotation thrombelastography to detect 
hypercoagulation state in patients with venous thromboembolism, using different 
assays. 
 
2. Evaluating the value of rotation thrombelastography in the diagnosis of 
thrombophilia. 
 
3. Comparing the coagulability of the two genders if measured by rotation 
thrombelastography. 
 
4. Testing the sensitivity of two assays, INTEG and nNATEG to sodium-
heparin and low molecular weight heparin.  
  
 
3.3. Materials and methods 
 
3.3.1. Subjects and preparation of blood and plasma samples 
 
Blood (10 ml) was collected from 66 healthy volunteers (age: 34.9±10.7 
years; male:female=32:34) and 55 consecutive patients (age: 37.6+12.6 years; 
male:female=12:43) with personal history of venous thromboembolic disease 
referred to our Haemostasis Outpatient Clinic using a 19 G needle and 10 ml native, 
silicone coated glass Vacutainer tubes and 5 ml Vacutainer tubes with buffered 
citrate (final concentration of sodium citrate in blood 12.9 mmol/l) after informed 
consent was obtained. All healthy subjects denied taking any medication that might 
affect platelet function or coagulation, in the two weeks preceding the experiments. 
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Patients with thromboembolic disease on oral anticoagulant therapy were converted 
to a prophylactic dose LMWH (typically 0.01 ml nadroparine/kg or 1 mg 
enoxaparine/kg once daily) at least 14 days before venipuncture. Blood was only 
taken at least 3 months after the last VTE event, after 12 h fasting, in morning 
hours, 24 hours after the last dose of LMWH. ROTEG® measurements, routine 
haemostatic tests (PT, aPTT, fibrinogen, TT) were performed typically between 0.5-
4 hours after venipuncture, except for the native blood samples which were tested 
immediately after venipuncture. The blood was kept in closed Vacutainer tubes at 
room temperature during the experiment. Plasma samples for specific factor 
determinations were centrifuged at 2000 g for 20 minutes, aliquoted and kept frozen 
at -70 C° until the tests were performed.  
 
3.3.2. Haemostatic assays and thrombophilia factor determinations 
 
Haemostatic assays 
 
Prothrombin time, fibrinogen, activated partial thromboplastin time, 
thrombin time, antithrombin, protein C, protein S activity and APC ratio were 
measured using an ACL 200 coagulation instrument and IL (Instrumentation 
Laboratory, Milano, Italy) reagents or kits according to the manufacturer’s 
instructions.  
The prothrombin time and the fibrinogen level was determined using the IL 
PT-Fibrinogen kit, which contains a recombinant rabbit tissue factor relipidated in a 
synthetic phospholipid blend and combined with calcium chloride, buffer and 
preservatives. In the PT-test, the addition of the reagent to the patient plasma 
initiates the activation of the extrinsic pathway. This results ultimately in the 
conversion of fibrinogen to fibrin, with formation of a solid gel. Fibrinogen is 
quantitated by relating the absorbance of light-scatter during clotting to a calibrator 
[118-120]. 
The APTT was determined using the IL TestTM APTT Lyophilized silica kit 
containing bovine cephalin and micronized silica as a contact activator, which is 
used to stimulate the production of factor XIIa by providing a surface for the 
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function of high molecular weight kininogen, kallikrein and FXIIa. This contact 
activation is allowed to proceed at 37°C for a specific period of time. Calcium is 
then added to trigger further reactions and the time required for clot formation is 
measured. Phospholipids are required to form complexes which activate factor X 
and prothrombin [121,122].  
The thrombin time was measured using IL TestTM Thrombin Time Kit. The 
addition of thrombin to the plasma samples results in the conversion of fibrinogen 
to fibrin, with the formation of solid gel. The time between addition of thrombin to 
the plasma sample and clot formation is thrombin time [123].  
Antithrombin activity was measured by using the IL Antithrombin kit, 
which is an assay based on a synthetic chromogenic substrate and on FXa 
inactivation. The measurement contains two stages: 1. Incubation of the plasma 
with the FXa reagent in presence of an excess of heparin. 2. Quantification of the 
residual FXa activity with a synthetic chromogenic substrate. The paranitroanilin 
released is monitored kinetically at 405 nm and is inversely proportional to the 
antithrombin level in the test sample [124]. 
Protein C functional activity was determined with IL TestTM ProClot kit 
based on the prolongation of an APTT assay in the presence of activated protein C. 
The anticoagulant effect of activated protein C is due to its sensitivity to FV and 
FVIII levels. APC in plasma samples is generated by Protac, a rapid in vitro PC 
activator derived from the venom of the copperhead snake Agkistrodon contortrix 
contortrix [125]. 
Protein S functional activity was determined with IL TestTM Protein S assay 
by measuring the degree of prolongation of a prothrombin time in the presence of 
bovine thromboplastin, calcium ions and activated protein C. The protein S activity 
is proportional to the prolongation of the PT of a protein S deficient plasma to 
which diluted sample has been added. Activated protein C is generated by 
activation of PS deficient plasma with Protac [126].  
APC resistance was determined using the IL TestTM APCTM Resistance V 
kit. Sample plasma is prediluted with Factor V Reagent Plasma and incubated with 
the APTT reagent for a standard period of time. Coagulation is triggered by the 
addition of CaCl2 in the absence and presence of APC and the time of clot 
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formation is recorded. The APC ratio is calculated with the following formula: APC 
ratio=APTT with APC/APTT without APC [127]. 
For the determination of lupus anticoagulants (LA) we used HemosIL™ 
LAC Screen and LAC Confirm tests. In LAC Screen test a simplified diluted 
Russell’s Viper Venom Test (DRVV) reagent is used to screen for the presence of 
lupus anticoagulants. In LAC Confirm test a phospholipid-rich DRVV reagent is 
applied to confirm the presence of lupus anticoagulants. Russell’s viper venom, in 
the presence of calcium, directly activates factor X (in the test sample). LAC Screen 
and LAC Confirm are therefore unaffected by contact factor abnormalities, factor 
VII, VIII and IX deficiencies or inhibitors [128].  
 
Immunologic assays 
 
For the measurement of the antithrombin and protein C antigen levels anti-human 
antithrombin polyclonal antibody (DAKO) and anti-human protein C polyclonal 
antibody were used on rocket electrophoresis system according to Laurell, 
respectively [129,16]. 
The free protein S antigen level in the samples was determined using the Coaliza 
Protein S Free kit (Chromogenix), which is based on a procedure described by 
Dahlback and colleagues. The microplate wells are precoated with C4BP, which has 
a very high affinity for binding free protein S antigen in plasma. After the sample 
and conjugate incubation, unbound material is washed away and bound protein S, in 
complex with C4BP is detected with the addition of a substrate-chromogen. The 
amount of color in the wells, when expressed in a double logarithmic scale, is 
directly proportional to the amount of free protein S antigen in the plasma sample 
[130]. 
Plasma homocysteine level determinations were performed by IMx 
homocysteine immunoassay on IMx Analyzer (Abbott) in the Department of 
Laboratory Medicine, Faculty of Medicine, University of Pécs, Hungary.  
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Molecular genetics  
 
FV:Q506 mutation analysis was performed according to Zöller and 
Dahlbaeck, FII G20210A mutation analysis according to Poort and co-workers 
publication [131,132]. 
 
3.3.3. Rotation thrombelastography  
 
We analyzed the blood samples by using modified thrombelastograph® 
coagulation analysis (ROTEG®; Pentapharm Co., Munich, Germany), which is 
based on the thrombelastograph® system (TEG®) after Hartert [133]. Technical 
details of the ROTEG® coagulation analyzer are described in the literature [134-
136]. TEG measures shear elastic modulus during clot formation and subsequent 
fibrinolysis (Figure 3.1.)  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Basic elements of rotation thrombelastography.  
 
 
 
 
 
 
Spring 
Rotating axis 
(+/  - 4.75°) 
Light source 
Detector 
Plastic  pin 
Cuvette with blood 
Fibrin  strands  and 
platelet aggregates 
between surfaces 
Heated cuvette  holder 
Ball  bearing 
 62
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Parameters of ROTEG®. 
 
 
ROTEG® shows good correlation with conventional TEG® determination 
[137], and an excellent reproducibility and precision [138]. In the literature, 
inconsistent references exist on the stability and reproducibility of TEG 
measurements after sample storage at room temperature. Depending on the 
references [139-141], TEG measurements produced accurate and reproducible 
results within 30 min up to 4 hours. The automatic pipetting system makes the 
ROTEG® coagulation analyzer easy to handle in daily routine. ROTEG® uses a ball-
bearing system for power transduction, which makes it less susceptible to 
mechanical stress, movement, and vibration. Furthermore, the activation of the test 
samples accelerates the measurement process and seems to enhance reproducibility 
when compared with conventional TEG analysis [142]. The main variables of 
ROTEG® analysis are "clotting time" (CT, time from start of measurement until the 
start of clot formation) corresponding to the reaction time (r time) in a conventional 
TEG, "clot formation time" (CFT, time from the beginning of clot formation until 
an amplitude of 20 mm is reached) in accordance with the coagulation time (k time), 
"maximum clot firmness" (MCF, which represents the maximum firmness which 
the clot has reached in this measurement, it is the maximal vertical expansion of the 
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thrombelastograph), which is equivalent to the maximum amplitude, and the alpha-
angle (this parameter is given by the angle between the centre line and a tangent to 
the curve through the 2 mm amplitude point, which represents the kinetics of clot 
formation), and the maximum lysis (ML, which represents the maximum 
fibrinolysis detected during the measurement. It is defined as the difference between 
the MCF and the lowest amplitude after reaching MCF during the measurement and 
is given as <% of MCF>) (Figure 3.2.).  
The following measurements were performed:  
1. Native TEG (nNATEG): native whole blood was placed into the test cell 
immediately after venipuncture and the test was started without delay.  
2. Non-activated TEG (NATEG): Just before running the assay, citrated 
blood samples were recalcified with 20 µL of CaCl2 0.2 M (Start-TEG; 
Pentapharm Co., Munich, Germany) and the test was started without an 
added activator.  
3. Intrinsic TEG (INTEG): NATEG + activation using surface activator 
(partial thromboplastin from rabbit brain, 20 µL of In-TEG reagent, 
Pentapharm Co., Munich, Germany) for monitoring the intrinsic system 
(factors XII, XI, IX, VIII, X, II, I and  platelets).  
4. Extrinsic TEG (EXTEG): NATEG + activation using tissue 
thromboplastin  (rabbit brain extract; 20 µL of Ex-TEG reagent, 
Pentapharm Co., Munich, Germany) for monitoring the extrinsic system 
(factors VII, X, V, II, I and platelets).  
In some cases, 16 µL of appropriate dilutions of nadroparine were added to 
the test cells before starting the measurement.  
 
3.3.4. Statistical analysis 
Results are reported as mean ± SD from the measurements conducted on 
different subgroup of patients or healthy volunteers. Statistical comparisons of 
samples were performed by paired and unpaired Student`s t-test or linear regression 
analysis using Microsoft Excel 2000. Differences were considered significant when 
p was < 0.05. 
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3.4. Results 
 
3.4.1. Comparison of patients with a history of thromboembolic disease and control 
subjects 
 
55 consecutive patients with personal history of venous thromboembolic 
disease referred to our Haemostasis Outpatient Clinic were tested. In the group of 
patients with thromboembolic anamnesis the CT in INTEG assay, the CFT in 
INTEG and EXTEG assays were significantly shorter, the MCF in INTEG and 
EXTEG assays and the alpha angle in INTEG and EXTEG assays were 
significantly higher when compared to the control group. (Figures 3.3. and 3.4.) 
There were no significant differences between the two groups in NATEG assay 
(Figure 3.5.). Surprisingly, when using nNATEG assay, CFT proved to be 
significantly longer and MCF and alpha angle significantly lower compared to the 
healthy volunteers (Figure 3.6.).  
   
 
Figure 3.3. Comparison of ROTEG® parameters of healthy volunteers (filled bars) 
and VTE patients (open bars) in INTEG test (recalcinated anticoagulated whole 
blood with contact activator) (data are mean±SD). 
 
 65
 
Figure 3.4. Comparison of ROTEG® parameters of healthy volunteers (filled bars) 
and VTE patients (open bars) in EXTEG test (recalcinated anticoagulated whole 
blood with tissue factor) (data are mean±SD). 
 
 
Figure 3.5. Comparison of ROTEG® parameters of healthy volunteers (filled bars) 
and VTE patients (open bars) in NATEG test (recalcinated anticoagulated whole 
blood) (data are mean±SD). 
 
 
 
 
 
 
 
 
Figure 3.6. Comparison of ROTEG® parameters of healthy volunteers and VTE 
patients in nNATEG test (native whole blood) (data are mean±SD). 
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3.4.2. Comparison of patients with positive and negative thrombophilia results 
 
Out of the examined 55 patients 34 (61%) proved to be thrombophilia (ThP) 
negative, 21 (39%) were ThP positive (13 FV Leiden heterozygotes, 2 FV Leiden 
homozygotes, 2 FII20210 heterozygotes, 1 lupus anticoagulant positive, 1 protein C 
deficient, 2 hyperhomocysteinaemia patients). When we compared the results of 
ThP negative and positive patients, we found no significant differences; although 
the CT and CFT values were still significantly lower if compared to the controls in 
case of the INTEG assay (Figure 3.7.).  
 
 
Figure 3.7. Comparison of ROTEG® parameters of healthy volunteers, 
thrombophilia positive and negative VTE patients in INTEG test (recalcinated 
anticoagulated whole blood with contact activator) (data are mean±SD). 
 
3.4.3. Effect of low molecular weight heparin on blood coagulation measured by 
ROTEG® 
 
Regarding the confusing results in nNATEG test, we carried out some 
additional experiments. As most of the VTE patients received LMWH prophylaxis 
during this period, we hypothesized a disturbing effect of LMW-heparin to the 
results. We tested the sensitivity of two ROTEG® assays (INTEG and nNATEG) to 
nadroparine, a commonly used low molecular weight heparin in vitro. We found, 
that nadroparine impairs whole blood coagulation in a dose dependent manner. The 
assay nNATEG was much more sensitive to low doses of nadroparine than INTEG 
(IC50s for clotting time were 0.65 and 15 U/ml, respectively) (Figure 3.8.). 
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Figure 3.8. Effect of nadroparine on blood coagulation in nNATEG (left) and 
INTEG (right) assays. Symbols represent the measured parameters. CT (diamond) 
and CFT (rectangle) is shown on the left y axis, whereas MCF (triangle) and alpha 
angle (x) is demonstrated on the right y axis.  
 
3.4.4. Effect of gender on blood coagulation measured by ROTEG® 
 
Observing that the male to female ratio was significantly different between 
patients and controls, we investigated, if there was a difference between the genders 
in the control group. The results showed that there were no significant differences in 
nNATEG, NATEG and INTEG parameters between male and female controls. In 
EXTEG, however, CT and CFT were significantly shorter; MCF and alpha-angle 
were higher in women compared to men (Figure 3.9.).  
 
 
 
 
 
 
 
 
Figure 3.9. Effect of gender on blood coagulation in EXTEG assay. Male data are 
represented in open bars, female data in closed bars. Data are mean±SD (n=58). 
Asterisk indicates statistical significance (*p<0.05). 
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3.5. Discussion  
 
The knowledge of the risk of a thrombotic event recurrence and its 
determinants is relevant to clinical policy regarding screening for thrombophilia, 
duration of anticoagulant treatment, and prophylactic strategies in circumstances of 
increased risk.  
The profile of whole blood coagulation by thrombelastography can be 
considered as an indirect measure of thrombin generation. One of the main features 
of classical TEG without added activators or anticoagulants was to maintain the 
physiologic conditions as much as possible. The new generation rotation 
thrombelastograph allies the naturality of classical TEG with the advantages of the 
modern medicine. Activated ROTEG® assays provide results much faster than 
conventional assays, and due to the mechanical modifications, described earlier, it 
can be used as point of care coagulation testing.   
In our study, we compared 66 healthy volunteers with 55 consecutive 
patients with personal history of venous thromboembolic disease referred to our 
Haemostasis Outpatient Clinic using the standard assays of the recently developed 
rotation thrombelastography. We demonstrated, that patients with previous 
thromboembolic disease were more hypercoagulable when compared to controls, 
using either by tissue factor or by contact activator activated assays. Previously 
TEG has shown a promising ability to detect known or established hypercoagulable 
states during pregnancy and postpartum [143-145], during the presence of cancer 
[146,147] and in association with surgery [148].  
Although the high sensitivity of TEG to hypercoagulability has been 
described in numerous studies, clear association between TEG parameters and 
thrombophilia has not been established. O’Donnel et al. examined thrombophilia 
patients, and concluded, that TEG cannot be used as a sole initial screening test in 
patients referred for thrombophilia testing, as it fails to identify 43% of underlying 
thrombophilic traits. TEG maybe a useful adjunctive test, particularly in patients in 
whom the regular thrombophilia screen proves unremarkable [112].  
 A study by Traverso et al. [149] included 100 patients undergoing elective 
abdominal surgery, and in the patients randomized to receive no postoperative 
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heparin thromboprophylaxis, TEG maximal amplitude (MA) value showed the 
ability to predict the occurrence of DVT with a sensitivity of 72.2% and specificity 
of 69%. Finally, Wilson et al. performed TEG every other day in 250 patients who 
had undergone proximal femoral fracture repair and showed that patients suffering 
from postoperative DVT had a significantly higher level of hypercoagulability as 
measured by TEG® than did those who did not suffer DVT [150]. Postoperative 
TEG® MA values in the hypercoagulable range are associated with a higher risk of 
postoperative thrombotic complications including pulmonary embolism, DVT, 
myocardial infarction, and ischemic stroke [108]. 
Miall et al. demonstrated that in a group of pregnant women there was a 
significant correlation between TEG parameters and PT, APTT and AT level, and 
mid trimester loss, but not with other thrombophilic defects [109]. Schreiber et al 
showed correlation between hypercoagulability determined by TEG after serious 
injury and female gender [110].  
Since the clinical parameters of patients and controls differed significantly in 
the male to female ratio, and previously a significant difference between ROTEG® 
profiles of genders was observed [140], we compared data between males and 
females. Females proved to be more hypercoagulable than males in case of tissue 
factor activated ROTEG®. Interestingly, Sorensen et al. described that in TEGs 
activated by minute amounts of tissue factor, females expressed a higher clot 
formation velocity as compared to males, which is consistent with our findings. On 
the other hand, the other assays (i.e. NATEG, INTEG, nNATEG) were not affected 
by genders. So despite the imbalance between the genders in our study, we can 
conclude that the results of the contact activator activated thrombelastography seem 
to be reasonable. After all, our findings of tissue factor activated 
thrombelastography are in accordance with those of Hvitfeldt et al., who 
investigated 34 venous and 42 arterial TE patients with activation by minute 
amounts of tissue factor, and found that patients with a history of venous or arterial 
thromboembolism had a significantly greater hypercoagulant whole blood 
coagulation as defined by a shortened clotting time together with an accelerated 
maximum velocity of clot propagation [107]. 
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In the nNATEG test, oddly, the VTE patients proved to be hypocoagulable 
when compared to the control group. As most of the patients received LMWH as 
VTE prophylaxis during the investigation, we suspected that the heparin had a role 
in this effect. Although we did not have the opportunity of measuring heparin 
concentration (anti-Xa activity) in these samples, the high sensitivity of nNATEG 
(it was almost 100 times more sensitive than INTEG) of both low molecular weight 
and unfractionated heparin could explain the apparent discrepancy of the results. 
However, using activated assays can eliminate the disturbing effect of heparin 
traces.  
Surprisingly, we did not find significant differences between the parameters 
of patients with thrombophilia proven by laboratory tests and those with no 
thrombophilia trait, although most of the found defects are not considered as severe 
thrombophilia. This and the relatively small case number may mask the differences 
detectable by ROTEG®. However, since the tested patients were clinically 
considered to have thrombophilia, the lack of difference between the two groups 
can also be explained by the existence of not yet identified prothrombotic 
abnormalities, which hold the same thrombotic event potential as the known ones.   
Although the differences between the thrombosis and the control group are 
small, and thus the assay is per se not capable of identifying patients with 
thrombotic tendency, there is a possibility of developing more sensitive assays 
based on rotation thrombelastography. 
In conclusion, our study indicated that rotation thrombelastography, first of 
all INTEG assay was able to detect hypercoagulability in patients with venous 
thromboembolism, which was independent of the presence of laboratorially 
detected thrombophilic traits.    
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4. Summary 
 
 
In this study, we have investigated two whole blood haemostasis methods to 
promote the research and treatment of cardiovascular disease and thrombophilia. 
 
As described in the first part of the work, we were the first to introduce a newly 
developed whole blood platelet function analyzer technique, the multiple platelet 
aggregometry.  
 
Our main results are:  
 
1. We indicated that MEA is a reliable, reproducible platelet aggregation 
method. Different platelet agonists induced platelet aggregation in donor-, time-, 
and dose dependent manner, which was not affected by platelet count within the 
normal platelet count range.  
2. We showed that when measured by MEA, as citrate seems to inhibit 
platelet aggregation, the use of the direct thrombin inhibitor lepirudin as an 
anticoagulant is preferable to the use of trinatrium citrate.  
3. Comparing MEA to SPC we found, that results are highly comparable, 
while SPC was much more time consuming than MEA.  
4. We concluded that MEA is able to detect the expected inhibitory effect of 
aspirin and apyrase to a greater extent than SPC.  
5. MEA could detect the inhibitory effect of selective ADP receptor 
antagonists in vitro.  
6. MEA was also capable of the ex vivo testing of clopidogrel effectivity. 
MEA may be a good candidate for further studies in large populations of 
cardiovascular patients.   
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In the second part, we investigated rotation thrombelastography in the 
detection of thrombophilia.  
 
Our main results are:  
 
1. Rotation thrombelastography was proved to detect thrombotic tendency in 
patient with former thromboembolism.   
2. We were the first to investigate the applicability of the most commonly 
used ROTEG® tests (nNATEG, NATEG, INTEG, EXTEG) in thrombophilia, and 
found that INTEG especially has the ability to detect hypercoagulable state. 
3. There was no difference between the ROTEG® parameters of TE patients 
with or without thrombophilic trait. This suggests that clinically both groups of 
patients had the same tendency to thrombosis, probably due to an underlying, so far 
unknown factor.  
4. In the group of healthy volunteers the women seemed to have a higher 
tendency to thromboembolism, when compared to the men, when we used the tissue 
factor activated test. 
5. Sodium-heparin and LMWH both inhibited the coagulation when 
measured by native or contact factor activated assay, the former being much more 
sensitive to both kinds of heparins.  
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